RedHill Biopharma (RDHL) Announces YELIVA Phase 1 Met All Primary Objectives in Adv. Solid Tumors
Tweet Send to a Friend
RedHill Biopharma Ltd. (Nasdaq: RDHL) announced positive final results from the Phase I study with YELIVA (ABC294640) in advanced solid ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
